SC 13G/A: iBio, Inc.
Ticker: IBIO · Form: SC 13G/A · Filed: 2024-11-14T00:00:00.000Z
Sentiment: neutral
Topics: sc-13g-a
AI Summary
SC 13G/A filing by iBio, Inc..
Risk Assessment
Risk Level: low
From the Filing
0001104659-24-119086.txt : 20241114 0001104659-24-119086.hdr.sgml : 20241114 20241114164852 ACCESSION NUMBER: 0001104659-24-119086 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20241114 DATE AS OF CHANGE: 20241114 GROUP MEMBERS: ADAR1 CAPITAL MANAGEMENT GP, LLC GROUP MEMBERS: DANIEL SCHNEEBERGER SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-84151 FILM NUMBER: 241463704 BUSINESS ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ADAR1 Capital Management, LLC CENTRAL INDEX KEY: 0001940272 ORGANIZATION NAME: IRS NUMBER: 000000000 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 3503 WILD CHERRY DRIVE STREET 2: BUILDING 9 CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 512-254-3790 MAIL ADDRESS: STREET 1: 3503 WILD CHERRY DRIVE STREET 2: BUILDING 9 CITY: AUSTIN STATE: TX ZIP: 78738 SC 13G/A 1 tm2428381d6_sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* iBio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 451033708 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: x Rule 13d-1(b) ¨ Rule 13d-1(c) ¨  Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“ Act ”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 451033708 1 Names of reporting persons ADAR1 Capital Management, LLC 2 Check the appropriate box if a member of a group (see instructions) (a) ¨ (b) x 3 SEC use only 4 Citizenship or place of organization    Texas Number of shares beneficially owned by each reporting person with: 5 Sole voting power 0 6 Shared voting power 966,298 (1) 7 Sole dispositive power 0 8 Shared dispositive power 966,298 (1) 9 Aggregate amount beneficially owned by each reporting person 966,298 10 Check if the aggregate amount in Row (9) excludes certain shares (see instructions) ¨ 11 Percent of class represented by amount in Row (9) 9.99% (2) 12 Type of reporting person (see instructions) OO (1) Includes (i) 443,113 shares of common stock, par value $0.001 per share (“Common Stock”) held by ADAR1 Partners, LP and (ii) 523,185 shares of Common Stock underlying pre-funded warrants and milestone warrants held by ADAR1 Partners, LP as of November 5, 2024. Excludes 832,955 shares of Common Stock underlying pre-funded warrants and milestone warrants held by ADAR Partners, LP, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the investment manager of AD